Allergic reaction to prasugrel and cross-reactivity with clopidogrel

Raccah, Bruria Hirsh; Shalit, Meir; Danenberg, Haim

doi:10.1016/j.ijcard.2011.09.051

Cited by 12 publications

(9 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Laboratory investigation revealed leukocytosis (12.9×10 9 /L), with elevated eosinophils (0.13×10 9 /L) and neutrophils (10.9×10 9 /L), as well as C-reactive protein ( (154) and extensive pruritic maculopapular rash (155). Symptoms occurred between 2 days-1 week of initiating prasugrel treatment (153)(154)(155).…”

Section: V)mentioning

confidence: 99%

“…It is still relatively soon to observe allergic reactions and cross-reactivity with this third generation thienopyridine, even though some cases of prasugrel HSR are reported in the literature. For example, Raccah et al describe a case of prasugrel rash in a patient with a history of clopidogrel itching cutaneous rash (155). On the other hand, clopidogrel was well-tolerated and efficient in a patient with prasugrel-induced drug-HSR and a history of clopidogrel treatment.…”

Section: B Cross-reactivitymentioning

confidence: 99%

“…Premature discontinuation of antiplatelet treatment following stent implantation is recognized as the main risk factor for developing thrombotic events, particularly stent thrombosis (4,117,155,161). For instance, Iakovou et al showed that 29% of patients who discontinued their treatment prematurely after drug eluting stent implantation develop stent thrombosis (162).…”

Section: Desensitization Protocolsmentioning

confidence: 99%

“…Suppressive therapy allowed symptoms resolution without treatment discontinuation in 22 (88.0%) patients (132). The importance of these studies is that short-course corticosteroids and antihistamines allow the management of clopidogrel HSR without treatment interruption, providing protection against CV adverse events (118,132,136,155,161).…”

Section: Suppressive Therapy With Corticosteroidsmentioning

confidence: 99%

“…Steroids and antihistamines led to improvement of clopidogrel cutaneous HSR (142, 147, 148), as well as prasugrel rash symptoms (155). Intravenous solumedrol and antihistamines were administered in a patient with clopidogrel maculopapular urticarial rash in which previous treatment with prednisone and antihistamines did not achieve relief from HSR symptoms (149).…”

Section: Suppressive Therapy With Corticosteroidsmentioning

confidence: 99%

See 4 more Smart Citations

Efficacy and Safety of Platelet Inhibitors

et al. 2013

View full text Add to dashboard Cite

Ischemic heart disease is the second leading cause of death in the world. The proportion of deaths resulting from this condition has decreased in the last two decades, mainly as a result of improved primary and secondary prevention of cardiovascular events, as well as the development of patient awareness and medical and pharmacological management. The purpose of the present review is to analyze pathophysiological events leading to platelet involvement in cardiovascular thrombosis, as well as the role of pharmacogenetics in modulating the risk of cardiovascular disorders. The present work was performed using a PubMed search with combinations of key words relevant to the subject in both English and French. In addition to the pharmacokinetic and pharmacodynamic characteristics of platelet inhibitors, this work reviews the efficacy and adverse events observed during the clinical trials with these drugs. This review further summarizes possible therapeutic drug monitoring strategies for antiplatelet drugs. The novelty of this work is the description of the lymphocyte toxicity assay as a specific method of diagnosing and predicting possible idiosyncratic adverse events attributable to antiplatelet medication. This article is open to POST-PUBLICATION REVIEW. Registered readers (see “For Readers”) may comment by clicking on ABSTRACT on the issue’s contents page.

show abstract